Download
s10875-021-01011-9.pdf 329,82KB
WeightNameValue
1000 Titel
  • Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient
1000 Autor/in
  1. Thalhammer, Julian |
  2. Maccari, Maria Elena |
  3. Wegehaupt, Oliver |
  4. Ehl, Stephan |
  5. Speckmann, Carsten |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-29
1000 Erschienen in
1000 Quellenangabe
  • 41(6):1365-1367
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s10875-021-01011-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310846/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Approximately 10% of children with newly diagnosed cancer have a cancer predisposition syndrome (CPS). The optimal diagnostic approach to identify them among children diagnosed with cancer is unknown.!##!Objective!#!To determine whether the use of a one-page questionnaire can improve the CPS diagnosis among children with an oncologic condition.!##!Design!#!Comparative effectiveness research.!##!Setting!#!Referral center for children with cancer.!##!Results!#!739 children diagnosed with an oncologic condition between 2012 and 2019. All children with a newly diagnosed oncologic condition presenting to Hannover Medical School between January 1st 2017 and December 31st 2019 were prospectively evaluated with a CPS questionnaire. Children in whom the questionnaire suggested the need of a genetic workup were further evaluated. All children diagnosed with an oncologic condition between January 1st 2012 and December 31st 2016 served as control. The CPS diagnoses established during both time periods were evaluated and compared. A CPS was diagnosed in 27 out of 287 children (9.4%) during the questionnaire period versus 24 out of 452 children (5.3%) during the control period (P = 0.032).!##!Conclusion!#!The CPS questionnaire appears to significantly improve the diagnosis of children with CPS among children with a newly diagnosed oncologic condition.
1000 Sacherschließung
lokal Female [MeSH]
lokal Fluorenes/therapeutic use [MeSH]
lokal Immunology
lokal Letter to Editor
lokal Humans [MeSH]
lokal Medical Microbiology
lokal Hepatitis C/genetics [MeSH]
lokal Infectious Diseases
lokal Benzimidazoles/therapeutic use [MeSH]
lokal Hepatitis C/drug therapy [MeSH]
lokal Antiviral Agents/therapeutic use [MeSH]
lokal Genotype [MeSH]
lokal STAT3 Transcription Factor/genetics [MeSH]
lokal Gain of Function Mutation/genetics [MeSH]
lokal Sofosbuvir/therapeutic use [MeSH]
lokal Child [MeSH]
lokal Internal Medicine
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-0226-1955|https://orcid.org/0000-0001-6488-7622|https://orcid.org/0000-0002-9391-0761|https://orcid.org/0000-0002-9265-2721|https://frl.publisso.de/adhoc/uri/U3BlY2ttYW5uLCBDYXJzdGVu
1000 Hinweis
  • DeepGreen-ID: 8ff1d6f5a7b34e8a87d907fd057207cc ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6446047.rdf
1000 Erstellt am 2023-04-28T12:01:50.886+0200
1000 Erstellt von 322
1000 beschreibt frl:6446047
1000 Zuletzt bearbeitet Fri Oct 13 15:26:15 CEST 2023
1000 Objekt bearb. Fri Oct 13 15:26:15 CEST 2023
1000 Vgl. frl:6446047
1000 Oai Id
  1. oai:frl.publisso.de:frl:6446047 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source